🇺🇸 FDA
Patent

US 11866502

Anti-FGFR2 antibodies and methods of use thereof

granted A61KA61K2039/505A61K45/06

Quick answer

US patent 11866502 (Anti-FGFR2 antibodies and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
65
CPC classes
A61K, A61K2039/505, A61K45/06, A61K47/68033, A61K47/68037